↓ Skip to main content

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

Overview of attention for article published in Molecular Cancer, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

blogs
1 blog
twitter
1 X user

Citations

dimensions_citation
194 Dimensions

Readers on

mendeley
123 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Published in
Molecular Cancer, June 2017
DOI 10.1186/s12943-017-0670-3
Pubmed ID
Authors

Hua-fu Zhao, Jing Wang, Wei Shao, Chang-peng Wu, Zhong-ping Chen, Shing-shun Tony To, Wei-ping Li

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status. Little progress in improving the prognosis of GBM patients has been made in the past ten years, urging the development of more effective molecular targeted therapies. Hyper-activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is frequently found in a variety of cancers including GBM, and it plays a central role in the regulation of tumor cell survival, growth, motility, angiogenesis and metabolism. Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors. Furthermore, combination of inhibitors targeting PI3K and other related pathways may exert synergism on suppressing tumor growth and improving patients' prognosis. Currently, only a handful of PI3K inhibitors are in phase I/II clinical trials for GBM treatment. In this review, we focus on the importance of PI3K/Akt pathway in GBM, and summarize the current development of PI3K inhibitors alone or in combination with other inhibitors for GBM treatment from preclinical to clinical studies.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 123 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 21 17%
Researcher 17 14%
Student > Master 15 12%
Student > Doctoral Student 10 8%
Student > Ph. D. Student 9 7%
Other 18 15%
Unknown 33 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 26 21%
Medicine and Dentistry 17 14%
Pharmacology, Toxicology and Pharmaceutical Science 11 9%
Agricultural and Biological Sciences 7 6%
Neuroscience 6 5%
Other 22 18%
Unknown 34 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2018.
All research outputs
#3,772,490
of 22,990,068 outputs
Outputs from Molecular Cancer
#247
of 1,731 outputs
Outputs of similar age
#68,069
of 317,335 outputs
Outputs of similar age from Molecular Cancer
#2
of 38 outputs
Altmetric has tracked 22,990,068 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,731 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,335 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.